Skip to main content

Table 4 Correlation between time to next treatment (TNT) and overall survival (OS)

From: Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

 

Spearman’s rho

95% CI

TNT1/OS1a

0.76

0.73–0.78

TNT2/OS2b

0.70

0.67–0.73

TNT3/OS3c

0.68

0.65–0.72

TNT4/OS4d

0.73

0.70–0.76

  1. aCalculated from the date of first-line treatment onset
  2. bCalculated from the date of second-line treatment onset
  3. cCalculated from the date of third-line treatment onset
  4. dCalculated from the date of fourth-line treatment onset